tradingkey.logo
tradingkey.logo
Search

Co-Diagnostics Inc

CODX
Add to Watchlist
1.640USD
+0.040+2.50%
Close 05/14, 16:00ETQuotes delayed by 15 min
114.53KMarket Cap
LossP/E TTM

Co-Diagnostics Inc

1.640
+0.040+2.50%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Co-Diagnostics Inc

Currency: USD Updated: 2026-05-13

Key Insights

Co-Diagnostics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 128 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 30.00.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Co-Diagnostics Inc's Score

Industry at a Glance

Industry Ranking
128 / 206
Overall Ranking
296 / 4487
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Co-Diagnostics Inc Highlights

StrengthsRisks
Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Growing
The company is in a growing phase, with the latest annual income totaling USD 622.49K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 622.49K.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 248.15K shares, decreasing 39.01% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 24.34K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.81.

Analyst Rating

Based on 2 analysts
Hold
Current Rating
30.000
Target Price
+1171.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-13

The current financial score of Co-Diagnostics Inc is 7.29, ranking 77 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 263.92K, representing a year-over-year increase of 76.74%, while its net profit experienced a year-over-year increase of 133.39%.

Score

Industry at a Glance

Previous score
7.29
Change
0

Financials

9.47

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.84

Operational Efficiency

3.00

Growth Potential

8.82

Shareholder Returns

7.32

Co-Diagnostics Inc's Company Valuation

Currency: USD Updated: 2026-05-13

The current valuation score of Co-Diagnostics Inc is 6.74, ranking 150 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.00, which is -13.33% below the recent high of -0.00 and -477446.67% above the recent low of -7.16.

Score

Industry at a Glance

Previous score
6.74
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 128/206
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-13

The current earnings forecast score of Co-Diagnostics Inc is 6.00, ranking 175 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 1.25, with a high of 1.50 and a low of 1.00.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts
Hold
Current Rating
30.000
Target Price
+1171.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

93
Total
4
Median
7
Average
Company name
Ratings
Analysts
Co-Diagnostics Inc
CODX
2
Boston Scientific Corp
BSX
37
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
35
Veeva Systems Inc
VEEV
30
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-13

The current price momentum score of Co-Diagnostics Inc is 6.92, ranking 84 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.45 and the support level at 1.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.09
Change
-0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
0.072
Neutral
RSI(14)
46.406
Neutral
STOCH(KDJ)(9,3,3)
21.608
Sell
ATR(14)
0.261
High Vlolatility
CCI(14)
-37.185
Neutral
Williams %R
91.406
Oversold
TRIX(12,20)
0.131
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
1.936
Sell
MA10
1.758
Sell
MA20
1.690
Sell
MA50
2.198
Sell
MA100
1.439
Buy
MA200
0.876
Buy

Institutional Confidence

Currency: USD Updated: 2026-05-13

The current institutional shareholding score of Co-Diagnostics Inc is 3.00, ranking 133 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 6.89%, representing a quarter-over-quarter decrease of 48.69%. The largest institutional shareholder is James Simons, holding a total of 24.34K shares, representing 0.68% of shares outstanding, with 58.60% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Orca Capital GmbH
62.86K
-14.04%
Private Advisory Group LLC
39.39K
--
Egan (Dwight H.)
28.73K
+15.21%
Renaissance Technologies LLC
Star Investors
24.34K
-15.81%
Abbott (Richard David)
23.22K
+6.01%
Brown (Brian Lee)
23.09K
+15.59%
Geode Capital Management, L.L.C.
14.97K
+40.37%
BlackRock Institutional Trust Company, N.A.
14.25K
--
Murphy (Ted)
9.39K
+8.33%
Serbin (Richard S)
10.97K
+21.17%
1
2

Risk Assessment

Currency: USD Updated: 2026-05-13

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Co-Diagnostics Inc is 1.04, ranking 198 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.28. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Co-Diagnostics Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Score

Industry at a Glance

Previous score
1.04
Change
0
Beta vs S&P 500 index
1.27
VaR
+8.27%
240-Day Maximum Drawdown
+86.62%
240-Day Volatility
+395.49%

Return

Best Daily Return
60 days
+3197.75%
120 days
+3197.75%
5 years
+3197.75%
Worst Daily Return
60 days
-60.54%
120 days
-60.54%
5 years
-60.54%
Sharpe Ratio
60 days
+1.96
120 days
+1.45
5 years
+0.44

Risk Assessment

Maximum Drawdown
240 days
+86.62%
3 years
+90.89%
5 years
+98.52%
Return-to-Drawdown Ratio
240 days
+4.56
3 years
+0.07
5 years
-0.17
Skewness
240 days
+15.32
3 years
+26.45
5 years
+34.09

Volatility

Realised Volatility
240 days
+395.49%
5 years
+194.15%
Standardised True Range
240 days
+9.11%
5 years
+13.06%
Downside Risk-Adjusted Return
120 days
+4171.72%
240 days
+4171.72%
Maximum Daily Upside Volatility
60 days
+6822.67%
Maximum Daily Downside Volatility
60 days
+5694.57%

Liquidity

Average Turnover Rate
60 days
+5.56%
120 days
+27.17%
5 years
--
Turnover Deviation
20 days
-81.23%
60 days
-42.32%
120 days
+181.96%

Peer Comparison

Healthcare Equipment & Supplies
Co-Diagnostics Inc
Co-Diagnostics Inc
CODX
5.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.73 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LivaNova PLC
LIVN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bruker Corp
Bruker Corp
BRKR
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI